Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.

Publication Details

Journal
Zurich Open Repository and Archive (University of Zurich)
Published
2024-09-01
DOI
https://doi.org/10.5167/uzh-262137
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

Zurich Open Repository and Archive (University of Zurich)
Diabetes Treatment and Management
article

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

article en

Abstract

This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.

Zurich Open Repository and Archive (University of Zurich)
Partnerships for the goals
Openalex Percentile: Top 54%
Diabetes Treatment and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany · Zurich Open Repository and Archive (University of Zurich) (2024) | TGRS Research Map | TGRS